A Phase 4 interventional study of Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops in Cataract, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-09.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.
Among the 12 studies testing moxifloxacin in Cataract, this one is the 6th largest by enrollment, is one of 2 that started in 2008, is one of 9 in phase 4, and was the 2nd registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 62 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
116 studies in Cataract by Alcon: 4 open now, 6 under way, none of them phase 3. Of 101 finished, 76 (75%) have results posted.
Among the 116 studies in Cataract by Alcon, this one is the 68th largest by enrollment of the 104 interventional ones that give a count, is one of 9 that started in 2008, is one of 23 in phase 4, and was the 28th registered.
Alcon’s Cataract studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing moxifloxacin in Cataract, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 116 in Cataract:
This tab as a report to print or save as PDF → With an account.
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug page: Moxifloxacin
1 drop every 6 hours into the study eye
The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.
The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon
Time frame: Day 15 after cataract surgery
The Percentage of Patients With no Ocular Pain
Time frame: Day 15 after cataract surgery
64 patients were enrolled into the study
| Milestone | Vigadexa Group |
|---|---|
| Started | 64 |
| Completed | 60 |
| Not completed | 4 |
| Withdrew: Physician decision | 2 |
| Withdrew: Lost to follow-up | 2 |
The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon
| Percentage of participants | Vigadexa Group |
|---|---|
| The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. | 91.7 |
| Percentage of participants | Vigadexa Group |
|---|---|
| The Percentage of Patients With no Ocular Pain | 96.7 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vigadexa Group | — | 0/64 (0%) | 0/64 (0%) |
| Age, Categorical(Participants) | Vigadexa Group |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 21 |
| >=65 years | 43 |
| Sex: Female, Male(Participants) | Vigadexa Group |
|---|---|
| Female | 37 |
| Male | 27 |
The record gives a start of Sep 2008 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin